December 21, 2022
Article
Results for Amgen’s Blincyto (blinatumomab) suggest it has efficacy as a treatment for Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
December 21, 2022
Article
Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.
December 20, 2022
Article
The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).
November 15, 2022
Article
Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.
November 14, 2022
Article
Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.
October 25, 2022
Article
Durability and toxicities such as cytokine release syndrome and immune effector-cell neurotoxicity syndrome are among the challenges.